Pluristem Enters into Licensing Agreement with TES Holdings

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

HAIFA, Israel, April 21, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PLTR ), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company’s IP coverage. This license follows Pluristem’s recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods.

The Japanese Patent No. 4554940 is titled “Drug containing human placenta-derived mesenchymal cells and process for producing VEGF employing said cells”. The patent covers use of all placenta-derived mesenchymal cells that are able to produce VEGF, a signaling protein that promotes the growth of new blood vessels, which the body needs to address the damage in ischemic tissue in the heart, brain, skeletal muscle, or elsewhere in the body. The listed inventors of the patent are Dr. Naohide Yamashita, Professor at the Department of Advanced Medical Science, University of Tokyo, Dr. Takashi Nakaoka, and Dr. Toshihide Nishishita. The patent is valid through 2023 and may be eligible for up to five years of patent term extension. Ischemic indications covered by the patent include the two leading causes of death worldwide – ischemic heart disease and stroke – as ranked by the World Health Organization , in addition to peripheral artery disease. Pluristem recently received clearance of its protocol for a Japanese pre-marketing trial in critical limb ischemia, a type of peripheral artery disease.

Akio Hayashi, President of TES Holdings, which manages the commercialization of this IP, commented, “Placenta-derived cell therapies may significantly improve the health and wellbeing of millions of people who suffer from ischemic disease. We are pleased that Pluristem, which is a leading player in the world’s regenerative medicine space, has licensed this patent because their unique experience with placental cell therapies make them optimally positioned to use knowledge developed at the University of Tokyo which demonstrates Japan’s strong capabilities in this space. We hope that this cooperation will advance the regenerative medicine industry and benefit the people with unmet medical needs.”

“The University of Tokyo is well known in for its cutting edge research in the field of cell therapy, and we are happy to expand our cooperation with this world class academic institution.  As we prepare to initiate a clinical trial in critical limb ischemia targeting conditional marketing approval via Japan’s new accelerated regulatory pathway for regenerative medicine, our patents addressing placental cell therapies remain a core asset and important to our current negotiations with large pharmaceutical companies regarding potential partnerships in Japan,” stated Pluristem Chairman and CEO Zami Aberman.

“This latest Japanese patent covers the use of placental treatments in any ischemic indication, including heart disease and stroke, which are multi-billion dollar markets. We are securing the IP landscape for placental cell therapies in Japan, which is particularly important because Japan is a large potential market for our cell products, together with the U.S. and Europe, and the world’s leader in facilitating the commercialization of regenerative medicines,” Aberman concluded.

About Ischemic Diseases

Ischemia is an insufficient supply of blood to an organ or tissue, usually due to a blocked artery. Myocardial ischemia can lead to a heart attack, which is the leading cause of death in the United states and Japan. Cerebral ischemia occurs when arteries are blocked in the brain, and can lead to a stroke, brain damage and death. About 80-85% of all strokes are ischemic. When cholesterol blocks the arteries in the leg, patients develop peripheral artery disease, which includes intermittent claudication and critical limb ischemia. The latter condition often leads to severe illness, amputation and death, and over a million patients suffer from it in the U.S. alone.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss the duration of the IP protection provided by the Japanese patent, when we discuss potential partnerships for the development and commercialization of our PLX cells in Japan, when we discuss our plan to obtain marketing approval in Japan via Japan’s accelerated regulatory pathway for regenerative medicines and when we discuss the market size with respect to heart disease and stroke. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact: Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 95

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 128

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 60

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 20

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 27

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing FPSO Market Set to Reach $174 Billion by 2031

Updated Category News Views 101

Insights into the Floating Production Storage Offloading Market The Floating Production Storage Offloading (FPSO) market is emerging as a cornerstone in the offshore oil and gas industry. As global oil demands continue to escalate, industries and stakeholders are directing their attention towards FPSO technologies, which combine production and storage capabilities to...

Continue Reading
3D Systems Corporation Faces Potential Securities Fraud Lawsuit

Updated Category News Views 207

Potential Securities Fraud Lawsuit Against 3D Systems Corporation Investors in 3D Systems Corporation have a significant opportunity as rumors of a securities fraud lawsuit surface. This potential lawsuit is connected to claims of misleading statements made by the company regarding its financial performance and market outlook. Overview of the Allegations According to...

Continue Reading
Latest Insights into the U.S. Real Estate Landscape Today

Updated Category News Views 368

Understanding Recent Trends in U.S. Real Estate In recent months, the real estate market in the United States has demonstrated some fascinating trends. Notably, many Americans are choosing to stay in their homes rather than moving. In fact, only 11% moved in a recent year, a stark contrast to historical figures where up to a third of the population changed residences...

Continue Reading
Venture Global, Inc. Investors Encouraged to Take Action Soon

Updated Category News Views 285

Important Deadlines for Venture Global, Inc. Investors Investors of Venture Global, Inc. should pay close attention to approaching deadlines related to an ongoing securities class action. Those who purchased stock pursuant to the company's initial public offering (IPO) that took place in early 2025 have significant rights that might not require any out-of-pocket expense....

Continue Reading
Vatn Systems Makes Strategic Acquisition to Boost AUV Tech

Updated Category News Views 160

Vatn Systems' Strategic Move to Enhance Underwater Technology In an exciting development for the defense technology sector, Vatn Systems has made a significant advancement by acquiring Crewless Marine. This decision is part of Vatn's strategy to improve its autonomous underwater vehicles (AUVs), highlighting the importance of acoustic capabilities in undersea warfare....

Continue Reading